Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study of the intravenous agent S65487 in relapsed or refractory hematologic cancers (acute myeloid leukemia, non-Hodgkin lymphoma, m…
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating a BCMA-GPRC5D-targeted CAR-T therapy in relapsed or refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma
Clinical trial update describing a managed access program for a combination treatment including belantamab mafodotin in multiple myeloma.
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 study of CM336 in relapsed or refractory multiple myeloma is ongoing and currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma [Phase 1]
A Phase 1 study of HG146 Capsule in Chinese subjects with relapsed and refractory multiple myeloma has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-10-09Clinical Trial Update: Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy [Phase 2]
A Phase 2 clinical trial evaluating an MRD-driven adaptive treatment strategy for newly diagnosed multiple myeloma using upfront daratumumab…
-
CLINICAL_TRIALS research · 2024-10-09Clinical Trial Update: Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Leuko Labs, Inc. is conducting a pivotal study to validate a novel non-invasive system for detecting severe neutropenia. The trial covers Di…
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes [NA]
This clinical trial update notes the termination of a study assessing whether sleep quality affects outcomes after hematopoietic cell transp…
-
CLINICAL_TRIALS trial_result · 2024-10-08Clinical Trial Update: Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy [Phase 2]
Phase 2 trial evaluating Descartes-08 consolidation therapy in high-risk multiple myeloma patients with residual disease after induction; th…
-
CLINICAL_TRIALS trial_result · 2024-10-04Clinical Trial Update: Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen [Phase 3]
This document reports the completed extension of a Phase 3 study evaluating allogeneic hematopoietic stem cell transplantation from haplotyp…
-
CLINICAL_TRIALS trial_result · 2024-10-03Clinical Trial Update: A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma [Phase 2]
Phase 2 study evaluating safety, tolerability, and efficacy of ACE-011 in patients with osteolytic lesions due to multiple myeloma has compl…
-
CLINICAL_TRIALS trial_result · 2024-10-03Clinical Trial Update: Study of the Immune Response After Vaccination in Multiple Myeloma Patients
This document provides an update on a completed clinical trial studying the immune response to vaccination in patients with multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2024-10-03Clinical Trial Update: Providing Cancer Care Closer to Home for Patients With Multiple Myeloma [NA]
The clinical trial NCT05971056 exploring delivery of cancer care closer to home for patients with multiple myeloma has been terminated.
-
CLINICAL_TRIALS withdrawal · 2024-10-03Clinical Trial Update: B-Cell Hematologic Malignancy Vaccination Registry
A clinical trial update indicates that the B-cell hematologic malignancy vaccination registry (NCT02298816) sponsored by Wake Forest Univers…
-
CLINICAL_TRIALS trial_result · 2024-10-02Clinical Trial Update: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 1, Phase 2]
This update reports the termination of a Phase 1/2 trial of TAK-981 in combination with monoclonal antibodies in adults with relapsed or ref…
-
CLINICAL_TRIALS research · 2024-10-02Clinical Trial Update: Two Schemes Response in Multiple Myeloma
Clinical trial update describing two treatment schemes showing response in multiple myeloma; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)
This completed non-interventional study in Germany assessed patient and healthcare provider satisfaction with subcutaneous versus intravenou…
-
CLINICAL_TRIALS trial_result · 2024-09-27Clinical Trial Update: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma [Phase 1]
Phase 1 results update for elranatamab (PF-06863135) in Japanese participants with relapsed or refractory multiple myeloma.
-
FDA approval · 2024-09-26FDA Approved: POMALIDOMIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for pomalidomide (generic pomalidomide).
-
CLINICAL_TRIALS research · 2024-09-26Clinical Trial Update: Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma [Phase 2]
This clinical trial update describes a Phase 2 study evaluating a combination of selinexor, daratumumab, carfilzomib, and dexamethasone for …
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma [NA]
This completed clinical trial evaluated geriatric-assessment interventions to address functional deficits in older adults with multiple myel…
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: Impact of Chemotherapeutic Treatments in Patients Aged 75 Years and Over Treated for Lymphoid Hematological Malignancy [NA]
Completed clinical trial assessing the impact of chemotherapeutic treatments in patients aged 75 and older with lymphoid hematological malig…
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial is evaluating BCMA-targeted CAR-T cells for relapsed/refractory multiple myeloma and is currently recruiting. The t…
-
CLINICAL_TRIALS trial_result · 2024-09-23Clinical Trial Update: Quality of Life the Danish Multiple Myeloma Patients
Completed clinical trial update from Odense University Hospital examining quality of life in Danish patients with multiple myeloma.
-
CLINICAL_TRIALS research · 2024-09-23Clinical Trial Update: AMG 701 Expanded Access Program
The AMG 701 expanded access program has ended and is no longer available to patients.